# A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

> **NCT04203797** · PHASE4 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** dupilumab
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT04203797
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2023-07-15
- **Final completion:** 2023-07-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203797, "A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04203797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*